These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389 [TBL] [Abstract][Full Text] [Related]
16. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Frassoldati A; Lamparelli T; Federico M; Annino L; Capnist G; Pagnucco G; Dini E; Resegotti L; Damasio EE; Silingardi V Leuk Lymphoma; 1994 Apr; 13(3-4):307-16. PubMed ID: 7519510 [TBL] [Abstract][Full Text] [Related]
17. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Robak T Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083 [TBL] [Abstract][Full Text] [Related]
18. Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2'-deoxyadenosine: implications for susceptibility to opportunistic infections. Siegal FP; Shodell M; Shah K; Drake D; Hoffman M; Sawitsky A; Janson D; Fitzgerald-Bocarsly P; Rai KR Leukemia; 1994 Sep; 8(9):1474-9. PubMed ID: 7916389 [TBL] [Abstract][Full Text] [Related]
19. Purine analog toxicity in patients with hairy cell leukemia. Tadmor T Leuk Lymphoma; 2011 Jun; 52 Suppl 2():38-42. PubMed ID: 21463124 [TBL] [Abstract][Full Text] [Related]